A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Trial Profile

A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Nabiximols (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 10 Aug 2016 Data expected in 4Q of 2016, as per GW Pharmaceuticals media release.
    • 10 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top